Relmada Therapeutics (RLMD) Enterprise Value Growth (3y) (2017 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Relmada Therapeutics | 595.35 Mn | 595.35 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20.89% |
| Dec 31, 2025 | 14.41% |
| Sep 30, 2025 | 57.75% |
| Jun 30, 2025 | 54.01% |
| Mar 31, 2025 | 50.32% |
| Dec 31, 2024 | 40.38% |
| Sep 30, 2024 | 14.99% |
| Jun 30, 2024 | 13.56% |
| Mar 31, 2024 | 6.63% |
| Dec 31, 2023 | 6.30% |
| Sep 30, 2023 | 4.79% |
| Jun 30, 2023 | 4.03% |
| Mar 31, 2023 | -4.84% |
| Dec 31, 2022 | -8.40% |
| Sep 30, 2022 | -186.27% |
| Jun 30, 2022 | -184.38% |
| Mar 31, 2022 | -375.38% |
| Dec 31, 2021 | -343.65% |
| Sep 30, 2021 | -363.00% |
| Jun 30, 2021 | -265.22% |
| Mar 31, 2021 | -188.94% |
| Dec 31, 2020 | -170.14% |
| Sep 30, 2020 | -197.33% |
| Jun 30, 2020 | -327.98% |
| Mar 31, 2020 | -246.74% |
| Dec 31, 2019 | -191.23% |
| Sep 30, 2019 | -8.06% |
| Jun 30, 2019 | -2.73% |
| Mar 31, 2019 | 43.44% |
| Dec 31, 2018 | 45.66% |
| Sep 30, 2018 | 64.09% |
| Jun 30, 2018 | 53.64% |
| Mar 31, 2018 | 45.95% |
| Dec 31, 2017 | 42.61% |
| Sep 30, 2017 | 44.49% |
| Jun 30, 2017 | 59.40% |
| Mar 31, 2017 | -3.88% |